Home › Pneumococcal Infections › NCT07135453
Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines
Novel Serotype Alert: Investigate New Pneumococcal Conjugate Vaccines for Inducing Cross-protection Against Newly Discovered Serotype 33E and Putative Novel Serogroup 33 Serotypes
Who can join
Ages 18 and older · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Healthy adult Exclusion Criteria: * No prior history of pneumococcal vaccination * No immunosuppressing medications or chronic diseases that affect immune function
About the study
The goal of this study is to learn whether different types of vaccines to prevent bacterial infections are able to effectively create antibodies that defend against certain types of bacteria.
We will give two different types of vaccine and evaluate the effectiveness of antibodies produced by each vaccine in killing bacteria.
What is being tested
- Pneumococcal Vaccine (biological)
Sponsor: University of Alabama at Birmingham · Participants: 70 · Started: Jul 1, 2026
Contact the study team
- David LaFon, MD · Phone: 2059343411
Official record on ClinicalTrials.gov — NCT07135453
Locations in the U.S.
| Alabama | University of Alabama at Birmingham, Birmingham |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.